Aspire Biopharma Holdings goes into its Monday earnings release with the borrow market completely exhausted — every share available to lend has already been borrowed, and the cost of doing so has hit its highest level in weeks.
The borrow picture is extreme. Availability has fallen to 0%, meaning there is not a single share left in the lending pool relative to estimated short interest. Cost to borrow has climbed to 239.9% annualised — up 25% on the week and the highest reading since late April. The ORTEX short score has risen sharply too, moving from 41 on May 5 to 80.8 on May 14, the second-highest level recorded across the past 10 sessions. When a stock's lending pool dries up entirely and borrowing costs run at nearly 240%, the setup is one where new short positioning is extremely expensive to establish or maintain.
That said, the raw short interest itself tells a more nuanced story. The headline figure of 0.1% of free float is negligible — far from the crowded levels that typically drive a squeeze narrative. What makes the week unusual is the volatility in the underlying series: estimated short shares swung from 2.5 million on May 8 down to just 83,000 on May 11, and then back up to 109,000 by May 14. That kind of intraday-scale churn in a stock with a market cap of under $1 million is characteristic of a thinly traded micro-cap where even small changes in borrow demand move the published metrics dramatically. The 515% week-on-week increase in shares short reflects those oscillations, not a structural build from a new bearish thesis.
Price has reflected the turbulence. ASBP closed at $5.61 on May 15, down 4.4% on the day and off 84% over the past month. That collapse from far higher levels has left the stock deeply dislocated — the kind of move that typically accompanies a sharp re-rating event or a capital raise. With no external news available and no analyst coverage visible in the dataset, the fundamental backdrop remains opaque. Institutional ownership is thinly spread: the two largest disclosed holders, Ardsley Advisory Partners and an individual named Kraig Higginson, together account for roughly 10.6% of shares. The only notable insider transactions on record — a director buying 20,000 shares at $0.39 in June 2025 — are stale by almost a year and predate the current price level entirely.
Historical earnings reactions have been large and unpredictable. The three most recent prints produced first-day moves of +12.8%, −13.2%, and +15.1%, with five-day follow-throughs in the same direction in two of those three cases. That track record of double-digit reactions — in either direction — amplifies the significance of the borrow cost sitting at 240% going into Monday's number.
The combination to watch on Monday is whether the earnings result and any accompanying disclosure can explain the month's 84% price collapse — and whether the locked lending pool loosens or tightens further after the print.
See the live data behind this article on ORTEX.
Open ASBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
